

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

**ITEM 1                      Name and Address of Company:**

OCUMETICS TECHNOLOGY CORP. (the “Corporation”)

1250, 639 – 5<sup>th</sup> Avenue SW  
Calgary, Alberta T2P 0M9

**ITEM 2                      Date of Material Change:**

July 7, 2026

**ITEM 3                      News Release:**

The news release was distributed on July 7, 2026 and filed on SEDAR on July 7, 2026.

**ITEM 4                      Summary of Material Change:**

The Corporation announced a proposed private placement of units.

**ITEM 5                      Full Description of Material Change:**

Ocumetics announced a proposed private placement (the “Offering”) of up to 5,000,000 units of the Corporation (“Units”) at a price of \$0.40 per Unit for gross proceeds of up to \$2,000,000. There will be no minimum subscription level for the Offering. Each Unit will consist of one common share in the share capital of the Corporation (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of \$0.50 for a period of three years from the date of issuance of the Warrant.

The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least \$0.75 per Common Share for a period of 30 consecutive trading days, the expiry date of the Warrants may be accelerated by the Corporation to a date that is not less than 30 days after the date that notice of such acceleration is provided to the Warrant holders by way of a press release.

Net proceeds of the Offering are expected to be used to fund the Corporation’s continuing first in-human clinical trials, for ongoing research and development and for general working capital. Although the Corporation intends to use the proceeds of the offering as described above, the actual allocation of proceeds may vary from the uses set out above, depending upon future operations, events or opportunities.

The Offering may include finder’s fees commissions payable in cash and/or securities and is subject to approval of the TSX Venture Exchange.

The Offering is expected to close in tranches. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue.

Insiders may participate in the Offering. Any participation by insiders in the Offering will constitute a

related party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions but is expected to be exempt from the formal valuation and minority shareholder approval requirements of that instrument.

The Corporation did not proceed with the offering of units previously announced on April 29, 2026.

**ITEM 6                      Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:**

Not Applicable.

**ITEM 7                      Omitted Information:**

Not Applicable.

**ITEM 8                      Executive Officer:**

Further information relating to this Material Change Report may be obtained from:

Roger Jewett, Chief Financial Officer  
Telephone: (403) 650-7718

**ITEM 9                      Date of Report:**

July 7, 2026

The foregoing accurately discloses the material change referred to in this report